SCHEMBL2540914

SCHEMBL2540914

O=c1oc2ccccc2c(Cl)c1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 5/20 0.53
GAA P10253 3/20 0.53
MAPT P10636 4/20 0.53
LMNA P02545 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
HTT P42858 1/20 0.53
TLR9 Q9NR96 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
HSD17B10 Q99714 2/20 0.52
CYP3A4 P08684 2/20 0.52
GLA P06280 1/20 0.52
HPGD P15428 1/20 0.52
PGAM1 P18669 1/20 0.52
MAOA P21397 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
TP53 P04637 2/20 0.50
CYP1A2 P05177 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27752820 0.82 HSD17B3 (0.60) ALDH1A1KDM4EGAAMAPTLMNA
SCHEMBL27752675 0.82 KDM4E (0.62) ALDH1A1KDM4EMAPTLMNASMN1; SMN2
SCHEMBL28320998 0.82 GAA (0.69) ALDH1A1KDM4EGAAMAPTLMNA
SCHEMBL5273182 0.79 CA9 (0.53) ALDH1A1KDM4EGAAMAPTLMNA
SCHEMBL28004955 0.77 ALDH1A1 (0.50) ALDH1A1KDM4EGAAMAPTLMNA
SCHEMBL28091429 0.76 PLA2G2A (0.53) KDM4EADORA3MEN1KMT2ANQO1
SCHEMBL30272141 0.76 LMNA (0.67) ALDH1A1GAAMAPTLMNAHTT
SCHEMBL2017838 0.76 LMNA (0.67) ALDH1A1GAAMAPTLMNAHTT
SCHEMBL15842804 0.75 AHR (0.50) ALDH1A1KDM4EGAALMNATDP1
SCHEMBL10336569 0.75 NQO1 (0.56) ALDH1A1KDM4EHSD17B10HPGDMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118791455-A Synthetic method for preparing 3, 4-dichloro coumarin from 4-chloro coumarin 广西大学 2024-10-18 CN claimed
CN-105884739-B A kind of synthetic method of benzo cumarin polycyclic compound 广西大学 2018-04-27 CN claimed
CN-105884739-A Synthetic method for benzocoumarin polycyclic compounds 广西大学 2016-08-24 CN claimed
US-9127092-B2 Method for producing polydienes and polydiene copolymers with reduced cold flow BRIDGESTONE CORPORATION (JP) 2015-09-08 US claimed
US-20140187725-A1 METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW BRIDGESTONE CORPORATION (JP) 2014-07-03 US claimed
CN-118791455-B Synthetic method for preparing 3, 4-dichloro coumarin from 4-chloro coumarin 广西大学 2025-09-30 CN disclosed
CN-118791455-B Synthetic method for preparing 3, 4-dichloro coumarin from 4-chloro coumarin 广西大学 2025-09-30 CN disclosed
CN-118791455-A Synthetic method for preparing 3, 4-dichloro coumarin from 4-chloro coumarin 广西大学 2024-10-18 CN disclosed
CN-118791455-A Synthetic method for preparing 3, 4-dichloro coumarin from 4-chloro coumarin 广西大学 2024-10-18 CN disclosed
CN-118791455-A Synthetic method for preparing 3, 4-dichloro coumarin from 4-chloro coumarin 广西大学 2024-10-18 CN disclosed
US-11400062-B2 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof SIGNATURE THERAPEUTICS, INC. (US) 2022-08-02 US disclosed
US-20220054479-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2022-02-24 US disclosed
US-20060142171-A1 Novel alkaline protease FORSKARPATENT I SYD AB (SE) 2006-06-29 US disclosed
EP-1611235-A1 NOVEL ALKALINE PROTEASE Forskarpatent i Syd AB (SE) 2006-01-04 EP disclosed
WO-2004085639-A9 NOVEL ALKALINE PROTEASE FORSKARPATENT I SYD AB (SE) 2005-11-10 WO disclosed
US-6916824-B1 Methods of treating cataracts and diabetic retinopathy with tricyclic pyrones KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2005-07-12 US disclosed
WO-2004085639-A1 NOVEL ALKALINE PROTEASE FORSKARPATENT I SYD AB (SE) 2004-10-07 WO disclosed
CN-1039967-C Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes, and 3-aminothiochromanes LILLY CO ELI (US) 1998-09-30 CN disclosed
EP-0615548-A1 NOVEL PROTEASES WITH DNA FRAGMENTING ACTIVITY UNIVERSITY OF MANITOBA (CA) 1994-09-21 EP disclosed
WO-1993011246-A1 NOVEL PROTEASES WITH DNA FRAGMENTING ACTIVITY UNIVERSITY OF MANITOBA (CA) 1993-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220054479-A1 OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE OPRM1, OPRK1, OPRD1 ALDH1A1 383/4885KDM4E 1535/4885GAA 82/4885
US-11400062-B2 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof ACHE, COMT, CES2 ALDH1A1 795/4885KDM4E 812/4885GAA 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.